Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions.
Morris
R E
RE
Department of Cardiovascular Surgery, Stanford University, School of Medicine, California 94305-5247.
Meiser
B M
BM
Wu
J
J
Shorthouse
R
R
Wang
J
J
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003524:Cyclosporins / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004357:Drug Synergism; D006085:Graft Survival; D006087:Graft vs Host Reaction; D016027:Heart Transplantation / Q000276:immunology*; D006789:Host vs Graft Reaction; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008198:Lymph Nodes / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D011090:Polyenes / Q000008:administration & dosage / Q000627:therapeutic use*; D020123:Sirolimus; D016559:Tacrolimus; D014184:Transplantation, Homologous
D000900:Anti-Bacterial Agents; D003524:Cyclosporins; D007166:Immunosuppressive Agents; D011090:Polyenes; D020123:Sirolimus; D016559:Tacrolimus